Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.

Onco Targets Ther · 2013 · PMC3540953 · PMID 23319868

Europe PMC DOI

hedged sentence

0.0894

closest p · 1.8× alpha

0.0894

boldest claim

The sentences

did not reach statistical significanceP = 0.0894so close (0.05 < p ≤ 0.1)

72 There was a trend for a higher percentage of patients with complete or near-complete pathological response after receiving abiraterone for 24 weeks vs 12 weeks prior to prostatectomy (34% vs 15%) that did not reach statistical significance ( P = 0.0894).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.